Study Summary: This study looks at HIV-1 treatments in people whose virus is under control. It has two parts. In Part A, researchers will compare two treatments: a new combination of drugs called GS-3242 and Lenacapavir (LEN) given as shots, versus a current medication called Biktarvy (B/F/TAF—this is a combination of three medicines: bictegravir, emtricitabine, and tenofovir alafenamide). This part lasts until Week 35. Part B compares the same treatments but ends at Week 26.
Key Points:
- This study involves switching medications and requires regular doctor visits for shots.
- Participants must have been on Biktarvy for at least 6 months with low virus levels.
- People who have used certain HIV treatments before cannot join this study.
How understandable was the trial content above?
Hard to understand
Easy to understand